Target intelligence / Profile preview

E3 ubiquitin-protein ligase Itchy homolog (ITCH)

Target
ITCH
Molecular classification
Enzyme, E3 ubiquitin ligase, HECT domain–containing protein
01

Overview

E3 ubiquitin-protein ligase Itchy homolog (ITCH) is an enzyme encoded by the *ITCH* gene on chromosome 20. As a member of the HECT domain-containing family of E3 ubiquitin ligases, it catalyzes the transfer of ubiquitin from an E2 conjugating enzyme to specific substrate proteins—marking them for proteasomal degradation. This process regulates numerous cellular functions including immune responses and signal transduction. In both mouse models ("Itchy" mice) and humans, loss-of-function mutations lead to profound immune system abnormalities—such as lymphoid hyperplasia and multi-organ inflammation—as well as developmental defects like altered growth patterns and craniofacial anomalies. The activity and specificity of ITCH are regulated by phosphorylation events mediated by kinases such as MAPK8/JNK; this controls downstream effects on transcription factors like JUNB. Through interactions with various signaling molecules—including CXCR4, c-Jun family members, NOTCH receptors—it plays a central role at multiple nodes within cell signaling networks relevant to immunity and development.

Other names
Itchy E3 ubiquitin protein ligaseItchITCH (gene/protein symbol)
02

Mechanism of action

Drugs or molecules that would target ITCH would likely act by: Modulating its E3 ubiquitin ligase activity to alter substrate degradation. Affecting its regulation by upstream kinases such as MAPK8/JNK pathway components. No approved drugs or clinical candidates specifically modulating ITCH are referenced.

03

Biological functions

Ubiquitination of target proteins for proteasomal degradationRegulation of immune response, including Th2 cytokine secretion and Interleukin 4 transcriptionControl of JUNB protein turnover and modulation of transcription factor activity via phosphorylation-dependent mechanismsRegulation of cell signaling pathways through interaction with multiple signaling proteins (e.g., c-Jun, NOTCH1)
04

Disease associations

Autoimmune disease (multisystem, with facial dysmorphism)Immune system dysfunctions (hyperplasia of lymphoid/hematopoietic cells, inflammation in stomach/lung in mice; aberrant immune function in humans)Developmental disorders (altered physical growth, craniofacial defects, defective muscle development in humans with ITCH deficiency)
05

Safety considerations

Immune dysregulation leading to autoimmunity or immunodeficiency.Possible developmental abnormalities if targeted during critical periods.

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase Itchy homolog (ITCH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase Itchy homolog (ITCH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call